Intersect ENT

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Intersect ENT and buy or sell other stocks, ETFs, and their options commission-free!

About XENT

Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. Its products include PROPEL and SINUVA. 

CEO
Thomas A. West, MBA
CEOThomas A. West, MBA
Employees
Employees
Headquarters
Menlo Park, California
HeadquartersMenlo Park, California
Founded
2003
Founded2003
Employees
Employees

XENT Key Statistics

Market cap
954.90M
Market cap954.90M
Price-Earnings ratio
-5.63
Price-Earnings ratio-5.63
Dividend yield
Dividend yield
Average volume
733.84K
Average volume733.84K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$28.25
52 Week high$28.25
52 Week low
$15.92
52 Week low$15.92

Stock Snapshot

With a market cap of 954.9M, Intersect ENT(XENT) trades at $28.24. The stock has a price-to-earnings ratio of -5.63.

On 2026-02-04, Intersect ENT(XENT) shares started trading at —, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 733.84K.

The stock's 52-week range extends from a low of $15.92 to a high of $28.25.

The stock's 52-week range extends from a low of $15.92 to a high of $28.25.

People also own

Based on the portfolios of people who own XENT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.